Earnings Releases·Nov 12, 2026, 4:45 PM ET

InspireMD — Third Quarter 2026 Earnings Summary

Q3 2026 total revenue declined 11.1% year-over-year to $2.242 million, driven by a $465,000 drop in U.S. sales due to the May 2026 recall, though international revenue rose 9.1% to $2.210 million; gross margin contracted to 10.7% from 34.2% in the prior year.
Net loss narrowed to $9.762 million ($0.12/share) from $12.708 million ($0.17/share) in the prior year, supported by a 26.7% reduction in operating expenses to $10.193 million, which included $1.074 million in restructuring costs.
The company received FDA approval for CGuard Prime for TCAR, enabling U.S. sales to commence in Q4 2026 and expanding the addressable market by over 35,000 procedures annually, with a PMA supplement for the CAS platform expected in December 2026.
Cash and cash equivalents decreased to $19.246 million as of September 30, 2026, from $54.211 million at year-end 2025, while management highlighted substantial doubt regarding the company's ability to continue as a going concern due to recurring losses and the need for additional capital.